Chronic Migraineurs Form Carboxyhemefibrinogen and Iron-Bound Fibrinogen
Autor: | Adam James DaDeppo, Evangelina B. Steinbrenner, Heidi Adelleen Hadley, Andrew Chen, Wendi Kulin, Ryan W. Matika, Vance G. Nielsen, John LaWall, Felesia Nancy MacFarland |
---|---|
Rok vydání: | 2015 |
Předmět: |
Male
medicine.medical_specialty Pathology Iron Fibrinogen Sodium Citrate Gastroenterology Body Mass Index chemistry.chemical_compound Chronic Migraine Internal medicine Sodium citrate medicine Humans Citrates Blood Coagulation Pharmacology Carbon Monoxide Vascular disease Chemistry General Neuroscience Anticoagulants Middle Aged Clot formation medicine.disease Heme oxygenase Kinetics Coagulation Chronic Disease Larva Migrans Visceral Clot strength Female medicine.drug |
Zdroj: | CNSneurological disorders drug targets. 14(8) |
ISSN: | 1996-3181 |
Popis: | Chronic migraine (CM) is a disabling painful condition that is associated with dementia and thrombotic disease. It has been proposed that carbon monoxide (CO) and iron may play a role in CM, and CO and iron are products of the heme oxygenase system which is widespread within the brain. Further, CO and iron enhance plasmatic coagulation in part via a fibrinogen-dependent mechanism. Thus, our goal was to determine whether patients with CM had experienced carboxyhemefibrinogen formation, iron bound fibrinogen formation and plasmatic hypercoagulability. Nonsmokers with CM were recruited after informed, written consent. Blood was collected, anticoagulated with sodium citrate, and then centrifuged with plasma stored at -80oC. Carboxyhemefibrinogen formation, iron bound fibrinogen formation and coagulation kinetics were determined via thrombelastographic methods. Patient results were compared with laboratory values generated from normal control plasmas. Incidence (95% confidence intervals) of the various parameters was determined using the Clopper-Pearson method. Twenty-six CM patients (24 female) were recruited; they were 46±12 years old. With regard to fibrinogen modification, 88.5% (69.8%-97.6%) of CM patients had formation of carboxyhemefibrinogen, iron bound fibrinogen, or both. With regard to coagulation, 42.3% (23.4%-63.1%) of patients had abnormally decreased time to clot initiation, 80.8% (60.6%-93.4%) had abnormally large velocity of clot formation, and 46.2% (26.6%-66.7%) had abnormally strong clot strength. Patients with CM have a large incidence of carboxyhemefibrinogen and iron bound fibrinogen formation and hypercoagulability. Confirmatory and potential therapeutic clinical trials targeting CO and iron modified hypercoagulation as a source of pain and vascular disease in CM patients are indicated. |
Databáze: | OpenAIRE |
Externí odkaz: |